Amelanotic acral melanomas: Clinicopathological, BRAF mutation, and KIT aberration analyses

• Published in: Journal of the American Academy of Dermatology Vol. 69; no. 5; pp. 700 - 707
• Main Authors: Choi, Yoo Duk, Chun, Seung Min, Jin, Sun A., Lee, Jee-Bum, Yun, Sook Jung
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2013
• Subjects: acral melanoma; Aged; amelanotic acral melanoma; amelanotic melanoma; BRAF mutation; Dermatology; Female; HMB-45; Humans; KIT mutation; Male; Melanoma, Amelanotic - genetics; Melanoma, Amelanotic - pathology; Mutation; prognosis; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins c-kit - genetics; KIT mutation; amelanotic acral melanoma; amelanotic melanoma; AJCC; HMB-45; acral melanoma; prognosis; AAM; PCR; BRAF mutation; American Joint Committee on Cancer; polymerase chain reaction
• ISSN: 0190-9622; 1097-6787; 1097-6787
• DOI: 10.1016/j.jaad.2013.06.035

Amelanotic acral melanoma (AAM) is very rare and difficult to diagnose both clinically and pathologically. Complete-type AAM shows no black to brown pigmentation in the lesion, whereas incomplete-type AAM shows focal or subtle pigmentation. AAM has been the subject of few investigations. We analyzed the clinicopathological features, BRAF mutations, and KIT aberrations in 35 Korean AAM cases. We included 28 cases of complete-type and 7 cases of incomplete-type AAM. In all, 26 AAMs (45.7%) were located on the feet of patients, 21 of which (82.9%) showed ulceration. Sixteen cases developed in subungual areas. Nodular melanoma was the most common histopathological subtype (63.6%). The most frequent cell types affected were epithelioid and spindled. HMB-45 staining was strongly positive in 66.7% of AAMs; 4 (12.1%) were negative for HMB-45, and 3 of these were complete-type AAMs. Of 33 total patients, BRAF mutations were detected in 2 AAM cases, and KIT aberrations were present in 11 cases (33.3%). Four cases (12.1%), all of which were complete-type AAMs, had KIT mutations. KIT aberrations were weakly correlated with c-kit staining. Twenty patients were TNM stage I or II, and mean survival was 30.14 ± 4.54 months. The study is limited by the small number of patients. Physicians should be aware of rare and hard-to-diagnose AAMs. We expect that tyrosine kinase inhibitors would be effective for KIT-mutated patients with complete-type AAMs.